Showing 1 - 8 results of 8 for search 'Xie L Xu', query time: 0.04s Refine Results
  1. 1
    Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

    Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study by Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos

    Published 2023-10-01
    Get full text
    Article
  2. 2
    Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

    Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis... by Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell

    Published 2023-03-01
    Get full text
    Article
  3. 3
    Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

    Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials by Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff

    Published 2024-02-01
    Get full text
    Article
  5. 5
    Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

    Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... by Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam

    Published 2024-02-01
    Get full text
    Article
  6. 6
    Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

    Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, plac... by Peter Nash, Atul Deodhar, Philip J Mease, Dafna D Gladman, Philip S Helliwell, Dennis G McGonagle, Alice Gottlieb, Elizabeth C Hsia, Chetan S Karyekar, Wolf-Henning Boehncke, Xie L Xu, Stephen Xu

    Published 2020-09-01
    Get full text
    Article
  7. 7
    Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

    Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studi... by Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease

    Published 2023-04-01
    Get full text
    Article
  8. 8
    Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

    Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study... by Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi

    Published 2021-04-01
    Get full text
    Article

Search Tools: